Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Conditions: Non-Small Cell Lung Cancer Interventions: Drug: Datopotamab Deruxtecan; Drug: Rilvegostomig; Drug: Pembrolizumab Sponsors: AstraZeneca; Daiichi Sankyo Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials